Company: NDRA
Filing Date: 2025-10-30
Form Type: 424B5
Source: 0001213900-25-103705
Chunk: 12

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-30
Form: 424B5
Chunk 12
---
 to $750,000 of Private Placement proceeds on the pilot validation study.

Corporate Information

We were incorporated in Delaware in July 2007.
Our corporate headquarters is located at 3600 Green Court, Suite 350, Ann Arbor, Michigan 48105-1570. Our website can be accessed
at www.endrainc.com. The telephone number of our principal executive office is (734) 335-0468. The information contained on, or that may
be obtained from, our website is not, and shall not be deemed to be, a part of this prospectus supplement or the accompanying prospectus.

Additional Information

You should rely only on the information contained
in this prospectus supplement or incorporated herein by reference. We have not authorized anyone to provide you with additional information
or information different from that contained in this prospectus supplement filed with the SEC or incorporated herein by reference. We
take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We
are offering to sell, and seeking offers to buy, the common shares and pre-funded warrants only in jurisdictions where offers and sales
are permitted. The information contained in this prospectus supplement is accurate only as of the date of this document, regardless of
the time of delivery of this prospectus supplement or any sale of the common shares and pre-funded warrants. Our business, financial condition,
results of operations, and prospects may have changed since the date hereof.

<div align='center'>S-7</div>

THE OFFERING

| Common stock offered by us                        |     | Shares of our common stock having an aggregate offering price of up to $1,750,000.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Common stock to be outstanding after the offering |     | Up to 1,497,880 shares, after giving effect to the sale of $1,750,000 of shares of our common stock at an assumed price of $5.28 per share, which was the closing price of our common stock on the Nasdaq Capital Market on October 28, 2025. The maximum number of shares that may be issued will vary depending on the price at which shares may be sold from time to time during this offering.(1)                                                                                                                                                                           |
| Manner of offering                                |     | “At the market offering,” as defined in Rule 415(a)(4) of the Securities Act, that may be made from time to time by the Sales Agent. We may also